Kowa Looks To License Drugs After Selling Japanese JV Stake To Teva
This article was originally published in PharmAsia News
Executive Summary
Japan's Kowa plans to license marketing rights for generic drugs of other pharmaceutical companies rather than engage in another joint venture, President Yoshihiro Miwa said in an interview